A citation-based method for searching scientific literature

Saira Khalique, Christopher J Lord, Susana Banerjee, Rachael Natrajan. Semin Cancer Biol 2020
Times Cited: 9







List of co-cited articles
62 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
226
44

Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Brian C Willis, Emily A Sloan, Kristen A Atkins, Mark H Stoler, Anne M Mills. Mod Pathol 2017
36
33

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Ronald L Chandler, Jeffrey S Damrauer, Jesse R Raab, Jonathan C Schisler, Matthew D Wilkerson, John P Didion, Joshua Starmer, Daniel Serber, Della Yee, Jessie Xiong,[...]. Nat Commun 2015
174
33

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund,[...]. Lancet Oncol 2012
549
33

Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Yuriko Uehara, Katsutoshi Oda, Yuji Ikeda, Takahiro Koso, Shingo Tsuji, Shogo Yamamoto, Kayo Asada, Kenbun Sone, Reiko Kurikawa, Chinami Makii,[...]. PLoS One 2015
32
33

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
662
33

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
Stephanie Lheureux, Anna Tinker, Blaise Clarke, Prafull Ghatage, Stephen Welch, Johanne I Weberpals, Neesha C Dhani, Marcus O Butler, Katia Tonkin, Qian Tan,[...]. Clin Cancer Res 2018
28
33

Clear cell carcinoma of the ovary: a clinical and molecular perspective.
Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington. Int J Gynecol Cancer 2021
19
33

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Hisham Abou-Taleb, Ken Yamaguchi, Noriomi Matsumura, Ryusuke Murakami, Hidekatsu Nakai, Koichiro Higasa, Yasuaki Amano, Kaoru Abiko, Yumiko Yoshioka, Junzo Hamanishi,[...]. Oncotarget 2016
16
22

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
540
22

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Saira Khalique, Kalnisha Naidoo, Ayoma D Attygalle, Divya Kriplani, Frances Daley, Anne Lowe, James Campbell, Thomas Jones, Michael Hubank, Kerry Fenwick,[...]. J Pathol Clin Res 2018
23
22

Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Stephanie Lheureux, Marsela Braunstein, Amit M Oza. CA Cancer J Clin 2019
331
22

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
393
22

ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
22

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Siân Jones, Tian-Li Wang, Ie-Ming Shih, Tsui-Lien Mao, Kentaro Nakayama, Richard Roden, Ruth Glas, Dennis Slamon, Luis A Diaz, Bert Vogelstein,[...]. Science 2010
842
22


BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
724
22


Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
931
22

Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers. Cancer Biol Med 2017
521
22


ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Jianfeng Shen, Yang Peng, Leizhen Wei, Wei Zhang, Lin Yang, Li Lan, Prabodh Kapoor, Zhenlin Ju, Qianxing Mo, Ie-Ming Shih,[...]. Cancer Discov 2015
249
22

Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Takafumi Kuroda, Hideaki Ogiwara, Mariko Sasaki, Kazuaki Takahashi, Hiroshi Yoshida, Takako Kiyokawa, Kazuki Sudo, Kenji Tamura, Tomoyasu Kato, Aikou Okamoto,[...]. Gynecol Oncol 2019
15
22

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Andrew J Yee, William I Bensinger, Jeffrey G Supko, Peter M Voorhees, Jesus G Berdeja, Paul G Richardson, Edward N Libby, Ellen E Wallace, Nicole E Birrer, Jill N Burke,[...]. Lancet Oncol 2016
122
22

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Joseph J Caumanns, G Bea A Wisman, Katrien Berns, Ate G J van der Zee, Steven de Jong. Biochim Biophys Acta Rev Cancer 2018
44
22

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Takeshi Fukumoto, Pyoung Hwa Park, Shuai Wu, Nail Fatkhutdinov, Sergey Karakashev, Timothy Nacarelli, Andrew V Kossenkov, David W Speicher, Stephanie Jean, Lin Zhang,[...]. Cell Rep 2018
42
22

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Hideaki Ogiwara, Kazuaki Takahashi, Mariko Sasaki, Takafumi Kuroda, Hiroshi Yoshida, Reiko Watanabe, Ami Maruyama, Hideki Makinoshima, Fumiko Chiwaki, Hiroki Sasaki,[...]. Cancer Cell 2019
98
22

ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Eleftherios P Samartzis, Aurelia Noske, Konstantin J Dedes, Daniel Fink, Patrick Imesch. Int J Mol Sci 2013
94
22

Cancer-Associated Mutations in Endometriosis without Cancer.
Michael S Anglesio, Nickolas Papadopoulos, Ayse Ayhan, Tayyebeh M Nazeran, Michaël Noë, Hugo M Horlings, Amy Lum, Siân Jones, Janine Senz, Tamer Seckin,[...]. N Engl J Med 2017
274
22

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Katrien Berns, Joseph J Caumanns, E Marielle Hijmans, Annemiek M C Gennissen, Tesa M Severson, Bastiaan Evers, G Bea A Wisman, Gert Jan Meersma, Cor Lieftink, Roderick L Beijersbergen,[...]. Oncogene 2018
43
22


Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan.
H Kobayashi, K Sumimoto, N Moniwa, M Imai, K Takakura, T Kuromaki, E Morioka, K Arisawa, T Terao. Int J Gynecol Cancer 2007
184
22

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.
Chris T Williamson, Rowan Miller, Helen N Pemberton, Samuel E Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati,[...]. Nat Commun 2016
169
22

Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Sarah E Taylor, Tianjiao Chu, Julia A Elvin, Robert P Edwards, Kristin K Zorn. Gynecol Oncol 2020
8
25


Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Rowan E Miller, Rachel Brough, Ilirjana Bajrami, Chris T Williamson, Simon McDade, James Campbell, Asha Kigozi, Rumana Rafiq, Helen Pemberton, Rachel Natrajan,[...]. Mol Cancer Ther 2016
53
22

Targeting EZH2 in cancer.
Kimberly H Kim, Charles W M Roberts. Nat Med 2016
738
22

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia,[...]. Nat Med 2015
383
22


ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Benjamin G Bitler, Shuai Wu, Pyoung Hwa Park, Yang Hai, Katherine M Aird, Yemin Wang, Yali Zhai, Andrew V Kossenkov, Ana Vara-Ailor, Frank J Rauscher,[...]. Nat Cell Biol 2017
115
22

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson. Gynecol Oncol 2018
31
22

Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study.
Shuang Ye, Jiaxin Yang, Dongyan Cao, Huimin Bai, Huifang Huang, Ming Wu, Jie Chen, Yan You, Jinghe Lang, Keng Shen. PLoS One 2015
13
22

Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Akira Tsuchiya, Michiie Sakamoto, Jun Yasuda, Makoto Chuma, Tsutomu Ohta, Misao Ohki, Toshiharu Yasugi, Yuji Taketani, Setsuo Hirohashi. Am J Pathol 2003
228
22


The target therapy of ovarian clear cell carcinoma.
Ying Jin, Yan Li, Lingya Pan. Onco Targets Ther 2014
19
22

Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Katsutoshi Oda, Junzo Hamanishi, Koji Matsuo, Kosei Hasegawa. Gynecol Oncol 2018
58
22

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson. Gynecol Oncol 2018
27
22

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
David R Crotzer, Charlotte C Sun, Robert L Coleman, Judith K Wolf, Charles F Levenback, David M Gershenson. Gynecol Oncol 2007
104
22

Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.
Boris Winterhoff, Habib Hamidi, Chen Wang, Kimberly R Kalli, Brooke L Fridley, Judy Dering, Hsiao-Wang Chen, William A Cliby, He-Jing Wang, Sean Dowdy,[...]. Gynecol Oncol 2016
29
22

Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Takafumi Kuroda, Takashi Kohno. Int J Clin Oncol 2020
7
28


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.